Tumor organoids from undifferentiated primary carcinomas to guide treatment choices
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Centre Francois Baclesse · NCT06612827
This project will grow tumor organoids from patients with undifferentiated primary carcinomas to try to predict which treatments might work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Francois Baclesse (other) |
| Locations | 1 site (Caen) |
| Trial ID | NCT06612827 on ClinicalTrials.gov |
What this trial studies
This observational project collects tumor and blood samples from adults with histologically confirmed undifferentiated primary carcinoma who are starting first‑line systemic therapy (or have received up to two cycles). Laboratory teams will attempt to establish patient‑derived tumoroids and run functional drug sensitivity tests to compare with patients' clinical responses. The approach aims to create a living biobank and to explore whether tumoroid testing can inform future treatment decisions. The work is conducted at a single center, Centre François Baclesse in Caen, France.
Who should consider this trial
Good fit: Adults with histological and immunohistochemical confirmation of undifferentiated primary carcinoma who are eligible for first‑line systemic treatment, have a life expectancy over three months, and can give informed consent.
Not a fit: People who are pregnant or breastfeeding, legally incapacitated, have a very short life expectancy, or whose tumor samples fail to form organoids are unlikely to gain benefit from the approach.
Why it matters
Potential benefit: If successful, the approach could help clinicians choose more effective therapies by testing drugs on a patient’s own tumor cells before giving treatment.
How similar studies have performed: Organoid‑based testing has shown promising ability to predict drug response in several cancer types in early studies, but it is not yet a standard clinical tool.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation * Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered. * Patient with life expectancy greater than 3 months * Patient of legal age * Patient affiliated to a social security scheme * Signature of informed consent prior to any specific study procedure Exclusion Criteria: * Persons deprived of their liberty or under guardianship (including curatorship) * Pregnant or breast-feeding patient
Where this trial is running
Caen
- Centre François Baclesse — Caen, France (RECRUITING)
Study contacts
- Study coordinator: zoé NEVIERE, Medical Doctor
- Email: z.neviere@baclesse.unicancer.fr
- Phone: 33231455050
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Undifferentiated Carcinoma, tumoroid, organoid